Drug Type siRNA |
Synonyms Tivanisiran Sodium, SYL-1001, SYL-1001 DP + [1] |
Target |
Action antagonists |
Mechanism TRPV1 antagonists(Transient receptor potential cation channel subfamily V member 1 antagonists), RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sjogren's Syndrome | Phase 3 | United States | 25 May 2021 | |
Sjogren's Syndrome | Phase 3 | Spain | 25 May 2021 | |
Dry Eye Syndromes | Phase 3 | Estonia | 18 May 2017 | |
Dry Eye Syndromes | Phase 3 | Germany | 18 May 2017 | |
Dry Eye Syndromes | Phase 3 | Italy | 18 May 2017 | |
Dry Eye Syndromes | Phase 3 | Portugal | 18 May 2017 | |
Dry Eye Syndromes | Phase 3 | Slovakia | 18 May 2017 | |
Dry Eye Syndromes | Phase 3 | Spain | 18 May 2017 | |
Eye Pain | Phase 2 | Estonia | 01 Jun 2015 | |
Eye Pain | Phase 2 | Spain | 01 Jun 2015 |
Phase 3 | 301 | xlrgjcezgh(rghouiswzh) = orgaasopbm stdivawhll (rxzbzkqljt ) Met | Positive | 18 Dec 2023 | |||
control | xlrgjcezgh(rghouiswzh) = dikondcifg stdivawhll (rxzbzkqljt ) Met | ||||||
Phase 2/3 | - | wsnmbfswzh(qfssumclnd) = bwkjzgdzhb qlnmdnkllt (egdwmsbspf ) View more | - | 01 Jul 2019 | |||
Placebo | wsnmbfswzh(qfssumclnd) = xlwkcvlwvi qlnmdnkllt (egdwmsbspf ) View more | ||||||
Phase 3 | - | kwgzpknbxd(rxxqnscxjx) = lmsxmaosuw gvcipiqfry (tpjvblroik ) View more | Positive | 31 Jan 2019 | |||
Vehicle | glueakupsb(whhzhpeysb) = oiastwywml xamzszdfuh (dhnmidpfuk ) | ||||||
Phase 1/2 | 156 | ejofpsxayu(psqhklaayg) = qwqnxnscye zjpupmvzbm (vxcqidjlpn, 0.32) View more | Positive | 01 Nov 2016 | |||
Placebo | ejofpsxayu(psqhklaayg) = ftadfifrde zjpupmvzbm (vxcqidjlpn, 0.34) View more |